An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
Closed to Enrollment
The purpose of this study is to test the safety of the experimental drug MFGR1877S and measure how the drug is processed at different dose levels in patients with multiple myeloma.
The dose of MFGR1877S you will receive will depend on how many patients have entered the study before you, since the dose will be gradually increased as the study proceeds. If you begin treatment with one of the lower doses of the study drug, it is possible that your dose of MFGR1877S may later be increased if a higher dose is shown to be safe and you are still receiving study treatment.
You will receive MFGR1877S on Days 1, 8 and 15 of the first treatment cycle and once every 28 days for Cycle 2 and any future treatment cycles. Cycles may be repeated up to one year after the first dose of the study drug.
You will be in the study for up to one year or until you experience unacceptable side effects to the study drug, or your multiple myeloma gets worse. You will be seen every three months for one year after the last dose of MFGR1877S or until you start another myeloma treatment.
Disease Status and/or Stage
Previously Treated t(4;14)-positive Multiple Myeloma
- Men and women age 18 and older
- Previously treated t(4;14)-positive multiple myeloma
- Detailed eligibility reviewed when you contact the study team
- June Greenberg, RN
- (212) 746-2651
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
For general inquiries, or if you need assistance finding a study, please contact:
Subject Recruitment Manager
Tel: (646) 962-9340